publicações selecionadas
-
artigo académico
- Unveiling the role of MGMT and DAPK hypermethylation in response to anti-EGFR agents: Molecular insights for advancing HNSCC treatment. Head and Neck. 2023
- Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGRF Inhibitors in KRAS Mutant Non-Small Cell Lung Cancer Cell Lines. International Journal of Molecular Sciences. 2022
- In Vitro and In Vivo Analysis of RTK Inhibitor Efficacy and Identification of Its Novel Targets in Glioblastomas.. Translational Oncology. 2013
-
artigo de conferência
-
artigo de revista
- Fractions Promote Cell Cycle Arrest and Inhibit Autophagic Flux in Human Cervical Cancer Cell Lines. Biomolecules. 2019
- Construction and characterization of a new TRAIL soluble form, active at picomolar concentrations.. Oncotarget. 2018
- AKT can modulate the in vitro response of HNSCC cells to irreversible EGFR inhibitors. Oncotarget. 2017
- Molecular characterization of short-term primary cultures and comparison with corresponding tumor tissue of Brazilian glioblastoma patients. Translational Cancer Research. 2017
- HER Family Receptors are Important Theranostic Biomarkers for Cervical Cancer: Blocking Glucose Metabolism Enhances the Therapeutic Effect of HER Inhibitors. Theranostics. 2017
- Cytotoxicity of allitinib, an irreversible anti-EGFR agent, in a large panel of human cancer-derived cell lines: KRAS mutation status as a predictive biomarker. Cellular Oncology. 2016
- In Vitro and In Vivo Analysis of RTK Inhibitor Efficacy and Identification of Its Novel Targets in Glioblastomas. Translational Oncology. 2013
-
documento
- Blocking glucose metabolism enhances the effect of HER inhibitors in cervical cancer therapy 2016
- Blocking glucose metabolism enhances the effect of HER inhibitors in cervical cancer therapy. 2016
- HER receptors are important theranostic biomarkers on cervical cancer: blocking glucose metabolism enhances the therapeutic effect of HER inhibitors 2016
- HER receptors are important theranostic biomarkers on cervical cancer: blocking glucose metabolism enhances the therapeutic effect of HER inhibitors. 2016